Israel approves Y-mabs cancer drug
The Danish-American biotech company will not be responsible for marketing the drug in the country, as Takeda holds the Israeli commercial rights.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
A collaboration between Takeda and Y-mabs on the commercialization of the latter’s two products, Danyelza (naxitamab) and omburtamab in Israel, is moving into a new phase.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Y-mabs reports second quarter sales increase for cancer drug
For subscribers
Takeda's profit shrank in Q1
For subscribers
Former CEO left Y-mabs with USD 10.7m in severance pay
For subscribers
